新普京(中国·澳门)娱乐场官方网站-PC platform
Stock Code
603707.SH
ABOUT
>
Company profile
Enterprise Culture
Early Warning System
BUSINESS
>
Commercialized Products
MEDIA
>
News in NKF
CONTACT
CH / EN
Home
>
MEDIA
>
News in NKF
>
【Explore the future of the pharmaceutical industry】 Kingfriend will meet you in CPHI Barcelona!
2023-10-17
【Explore the future of the pharmaceutical industry】 Kingfriend will meet you in CPHI Barcelona!
share
Return
Previous
Nothing at all
Next
Kindos creates the new record for fastest approval by FDA: Dacarbazine for Injection
Relevant recommendations
2024-08-07
NKF's subsidiary Kindos’s self-developed Ropivacaine Hydrochloride Injection gets FDA approval for marketing
2024-06-27
Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for YUSIMRY®, a Biosimilar of Humira®
2024-05-20
Eptifibatide injection approved by USFDA，from Nanjing King-Friend subsidiary
2024-05-14
Enoxaparin Sodium Injection of NKF approved in Egypt
2024-05-14
Kindos’ (subsidiary of NKF) Bortezomib for injection getting approved by NMPA, submitted to NMPA and US FDA
